Pharmaceutical Technology on MSN
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply ...
SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”) Fast Track is designed to expedite the ...
Satellos Bioscience's shares jumped Monday after the Duchenne treatment being developed by the biotechnology company received fast track designation in the U.S. In morning trading, the shares rose 12% ...
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...
FDA fast track designation supports development of pelareorep plus bevacizumab/FOLFIRI in 2L KRAS-mutant MSS mCRC, enabling more frequent regulatory engagement and potential accelerated pathways.
FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a serious condition with significant unmet medical need Designation supports enhanced ...
CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today ...
The U.S. Food and Drug Administration started taking applications for its PreCheck pilot, a new effort to accelerate the construction and review of pharmaceutical manufacturing facilities in the ...
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Merakris Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MTX-001, ...
BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, ...
Fast Track status aims to accelerate development of an autologous dendritic cell immunotherapy for advanced cutaneous melanoma with limited durable benefit from current standards in many patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results